| Investor | Avoro Capital Advisors LLC |
13D/G Filings
This page shows a list of all the recent 13D/G filings made by Avoro Capital Advisors LLC . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).
When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.
| Date | Form | Target | Prev Shares |
Current Shares |
Change (Percent) |
Ownership (Percent) |
Change (Percent) |
|
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | 13G/A | CNTA / Centessa Pharmaceuticals plc - Depositary Receipt (Common Stock) | 14,555,555 | 11,430,455 | ||||
| 2026-05-15 | 13G/A | SLNO / Soleno Therapeutics, Inc. | 2,900,000 | 2,300,000 | ||||
| 2026-05-15 | 13G | DMRA / Damora Therapeutics, Inc. | 3,783,000 | |||||
| 2026-05-15 | 13G/A | XENE / Xenon Pharmaceuticals Inc. | 5,666,666 | 5,777,777 | ||||
| 2026-05-15 | 13G | AVTX / Avalo Therapeutics, Inc. | 1,410,000 | |||||
| 2026-05-14 | 13D/A | WHWK / Whitehawk Therapeutics, Inc. | 11,914,961 | 18,292,675 | ||||
| 2026-02-17 | 13G/A | QURE / uniQure N.V. | 3,625,000 | 6,150,000 | ||||
| 2026-02-17 | 13G/A | CNTA / Centessa Pharmaceuticals plc - Depositary Receipt (Common Stock) | 10,808,080 | 14,555,555 | ||||
| 2026-02-17 | 13G | CELC / Celcuity Inc. | 3,111,111 | |||||
| 2026-02-17 | 13G/A | RNAM / Avidity Biosciences, Inc. | 9,935,792 | 8,515,792 | ||||
| 2026-02-17 | 13G | SLNO / Soleno Therapeutics, Inc. | 2,050,000 | 2,900,000 | ||||
| 2026-02-17 | 13G | DFTX / Definium Therapeutics, Inc. | 5,000,000 | |||||
| 2025-11-14 | 13G/A | FOLD / Amicus Therapeutics, Inc. | 20,500,000 | 15,025,000 | ||||
| 2025-11-14 | 13G/A | GLUE / Monte Rosa Therapeutics, Inc. | 3,725,000 | 0 | ||||
| 2025-11-14 | 13G | CNTA / Centessa Pharmaceuticals plc - Depositary Receipt (Common Stock) | 10,808,080 | |||||
| 2025-11-14 | 13G/A | MLTX / MoonLake Immunotherapeutics | 4,150,000 | 2,000,000 | ||||
| 2025-11-14 | 13G | GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) | 0 | 16,216,665 | ||||
| 2025-08-14 | 13G/A | BPMC / Blueprint Medicines Corporation | 3,850,000 | 375,000 | ||||
| 2025-08-14 | 13G/A | SLNO / Soleno Therapeutics, Inc. | 2,181,000 | 2,050,000 | ||||
| 2025-08-14 | 13G/A | GLUE / Monte Rosa Therapeutics, Inc. | 4,345,000 | 3,725,000 | ||||
| 2025-08-14 | 13G/A | ARWR / Arrowhead Pharmaceuticals, Inc. | 12,028,552 | 11,517,441 | ||||
| 2025-08-14 | 13G/A | TRML / Tourmaline Bio, Inc. | 2,222,222 | 2,555,555 | ||||
| 2025-08-14 | 13G | QURE / uniQure N.V. | 3,625,000 | |||||
| 2025-08-14 | 13G | MLTX / MoonLake Immunotherapeutics | 4,150,000 | |||||
| 2025-05-15 | 13G/A | BCRX / BioCryst Pharmaceuticals, Inc. | 13,050,000 | 8,700,000 | ||||
| 2025-05-15 | 13G | BPMC / Blueprint Medicines Corporation | 3,850,000 | |||||
| 2025-05-15 | 13G/A | FOLD / Amicus Therapeutics, Inc. | 23,175,000 | 20,500,000 | ||||
| 2025-03-04 | 13D/A | WHWK / Whitehawk Therapeutics, Inc. | 3,581,961 | 11,914,961 | ||||
| 2025-02-14 | 13G/A | ARWR / Arrowhead Pharmaceuticals, Inc. | 8,888,888 | 12,028,552 | ||||
| 2025-02-14 | 13G/A | GLUE / Monte Rosa Therapeutics, Inc. | 4,535,000 | 4,345,000 | ||||
| 2025-02-14 | 13G/A | VERA / Vera Therapeutics, Inc. | 4,309,590 | 5,610,000 | ||||
| 2024-12-23 | 13D/A | WHWK / Whitehawk Therapeutics, Inc. | 3,471,752 | 3,581,961 | ||||
| 2024-11-14 | 13G | TSHA / Taysha Gene Therapies, Inc. | 23,094,444 | |||||
| 2024-11-14 | 13G | TRML / Tourmaline Bio, Inc. | 2,222,222 | |||||
| 2024-11-14 | 13G | RNAM / Avidity Biosciences, Inc. | 9,935,792 | |||||
| 2024-11-14 | 13G | ARWR / Arrowhead Pharmaceuticals, Inc. | 8,888,888 | |||||
| 2024-11-14 | 13G | OCUL / Ocular Therapeutix, Inc. | 12,714,874 | |||||
| 2024-11-14 | 13G | SLNO / Soleno Therapeutics, Inc. | 2,181,000 | |||||
| 2024-11-14 | 13G/A | SYRE / Spyre Therapeutics, Inc. | 1,839,138 | 885,059 | ||||
| 2024-11-14 | 13G | VERA / Vera Therapeutics, Inc. | 4,309,590 | |||||
| 2024-11-14 | 13G/A | MRNS / Marinus Pharmaceuticals, Inc. | 3,150,000 | 0 | ||||
| 2024-11-14 | 13G/A | VRCA / Verrica Pharmaceuticals Inc. | 6,583,332 | 0 | ||||
| 2024-11-14 | 13G/A | GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) | 6,999,999 | 0 | ||||
| 2024-11-14 | 13G/A | FOLD / Amicus Therapeutics, Inc. | 27,400,000 | 23,175,000 | ||||
| 2024-11-14 | 13G/A | KYMR / Kymera Therapeutics, Inc. | 3,775,000 | 7,750,000 | ||||
| 2024-11-14 | 13G/A | ASND / Ascendis Pharma A/S | 3,755,555 | 4,988,888 | ||||
| 2024-04-23 | 13G/A | SYRE / Spyre Therapeutics, Inc. | 2,125,597 | 1,839,138 | ||||
| 2024-02-14 | 13G/A | KRYS / Krystal Biotech, Inc. | 1,410,000 | 2,565,555 | ||||
| 2024-02-14 | 13G/A | APLS / Apellis Pharmaceuticals, Inc. | 10,625,000 | 13,411,111 | ||||
| 2024-02-14 | 13G/A | FOLD / Amicus Therapeutics, Inc. | 26,800,000 | 27,400,000 | ||||
| 2024-02-14 | 13G/A | MDGL / Madrigal Pharmaceuticals, Inc. | 1,660,000 | 2,288,888 | ||||
| 2024-02-14 | 13G/A | MRSN / Mersana Therapeutics, Inc. | 7,550,000 | 0 | ||||
| 2024-02-14 | 13G/A | PMVP / PMV Pharmaceuticals, Inc. | 3,060,000 | 0 | ||||
| 2024-02-14 | 13G/A | ASND / Ascendis Pharma A/S | 3,100,000 | 3,755,555 | ||||
| 2024-02-14 | 13G/A | KYMR / Kymera Therapeutics, Inc. | 3,850,000 | 3,775,000 | ||||
| 2024-02-14 | 13G/A | GLUE / Monte Rosa Therapeutics, Inc. | 4,325,000 | 4,535,000 | ||||
| 2024-02-14 | 13G/A | MRTX / Mirati Therapeutics, Inc. | 5,555,555 | 4,886,840 | ||||
| 2024-02-14 | 13G/A | XENE / Xenon Pharmaceuticals Inc. | 4,900,000 | 5,666,666 | ||||
| 2024-02-14 | 13G | VRCA / Verrica Pharmaceuticals Inc. | 6,583,332 | |||||
| 2024-02-14 | 13G/A | CBAY / CymaBay Therapeutics, Inc. | 12,800,000 | 16,337,739 | ||||
| 2024-02-14 | 13G | SYRE / Spyre Therapeutics, Inc. | 2,125,597 | |||||
| 2024-02-14 | 13G | GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) | 6,999,999 | |||||
| 2024-02-14 | 13G/A | UTHR / United Therapeutics Corporation | 2,865,000 | 2,858,888 | ||||
| 2024-02-14 | 13G/A | MRNS / Marinus Pharmaceuticals, Inc. | 3,150,000 | 3,150,000 | ||||
| 2024-02-14 | 13G | BCRX / BioCryst Pharmaceuticals, Inc. | 13,050,000 | |||||
| 2024-02-14 | 13G/A | IOBT / IO Biotech, Inc. | 2,055,883 | 0 | ||||
| 2023-02-14 | 13G/A | XENE / Xenon Pharmaceuticals Inc. | 4,985,000 | 4,900,000 | ||||
| 2023-02-14 | 13G/A | GLUE / Monte Rosa Therapeutics, Inc. | 3,311,434 | 4,325,000 | ||||
| 2023-02-14 | 13G/A | MRSN / Mersana Therapeutics, Inc. | 6,800,000 | 7,550,000 | ||||
| 2023-02-14 | 13G | KYMR / Kymera Therapeutics, Inc. | 3,850,000 | |||||
| 2023-02-14 | 13G/A | APLS / Apellis Pharmaceuticals, Inc. | 8,555,555 | 10,625,000 | ||||
| 2023-02-14 | 13G/A | ISEE / IVERIC bio Inc | 7,250,000 | 6,750,000 | ||||
| 2023-02-14 | 13G/A | MDGL / Madrigal Pharmaceuticals, Inc. | 1,425,000 | 1,660,000 | ||||
| 2023-02-14 | 13G/A | FOLD / Amicus Therapeutics, Inc. | 18,500,000 | 26,800,000 | ||||
| 2023-02-14 | 13G/A | MRNS / Marinus Pharmaceuticals, Inc. | 3,235,000 | 3,150,000 | ||||
| 2023-02-14 | 13G/A | PMVP / PMV Pharmaceuticals, Inc. | 1,465,000 | 3,060,000 | ||||
| 2023-02-14 | 13G | KRYS / Krystal Biotech, Inc. | 1,410,000 | |||||
| 2023-02-14 | 13G/A | MRTX / Mirati Therapeutics, Inc. | 5,075,000 | 5,555,555 | ||||
| 2023-02-14 | 13G/A | UTHR / United Therapeutics Corporation | 3,035,000 | 2,865,000 | ||||
| 2023-02-14 | 13G | DICE / DICE Therapeutics Inc | 2,525,555 | |||||
| 2023-02-14 | 13G/A | KURA / Kura Oncology, Inc. | 4,000,000 | 3,105,000 | ||||
| 2023-02-14 | 13G | ASND / Ascendis Pharma A/S | 3,100,000 | |||||
| 2023-02-14 | 13G/A | IOVA / Iovance Biotherapeutics, Inc. | 8,675,000 | 7,020,000 | ||||
| 2023-02-14 | 13G/A | ADVM / Adverum Biotechnologies, Inc. | 6,950,000 | 0 | ||||
| 2022-09-26 | 13D/A | AADI / Aadi Bioscience, Inc. | 2,211,752 | 3,471,752 | ||||
| 2022-02-11 | 13G/A | PNT / POINT Biopharma Global Inc. | 0 | |||||
| 2022-02-11 | 13G/A | FENC / Fennec Pharmaceuticals Inc. | 1,670,000 | 1,200,000 | ||||
| 2022-02-11 | 13G/A | RLMD / Relmada Therapeutics, Inc. | 1,525,000 | 0 | ||||
| 2022-02-11 | 13G/A | PMVP / PMV Pharmaceuticals, Inc. | 2,350,267 | 1,465,000 | ||||
| 2022-02-11 | 13G/A | AVDL / Avadel Pharmaceuticals plc | 4,365,000 | 1,670,000 | ||||
| 2022-02-11 | 13G/A | ARNA / Arena Pharmaceuticals Inc | 4,190,000 | 1,235,000 | ||||
| 2022-02-11 | 13G | IOBT / IO Biotech, Inc. | 2,055,883 | |||||
| 2022-02-11 | 13G | FOLD / Amicus Therapeutics, Inc. | 11,200,000 | 18,500,000 | ||||
| 2022-02-11 | 13G | GLUE / Monte Rosa Therapeutics, Inc. | 3,311,434 | |||||
| 2022-02-11 | 13G/A | IOVA / Iovance Biotherapeutics, Inc. | 7,500,000 | 8,675,000 | ||||
| 2022-02-11 | 13G | APLS / Apellis Pharmaceuticals, Inc. | 8,555,555 | |||||
| 2022-02-11 | 13G/A | CBAY / CymaBay Therapeutics, Inc. | 10,300,000 | 12,800,000 | ||||
| 2022-02-11 | 13G/A | MDGL / Madrigal Pharmaceuticals, Inc. | 1,225,000 | 1,425,000 | ||||
| 2022-02-11 | 13G/A | MRNS / Marinus Pharmaceuticals, Inc. | 3,232,142 | 3,235,000 | ||||
| 2022-02-11 | 13G/A | ADVM / Adverum Biotechnologies, Inc. | 8,000,000 | 6,950,000 | ||||
| 2022-02-11 | 13G/A | UTHR / United Therapeutics Corporation | 2,850,000 | 3,035,000 | ||||
| 2022-02-11 | 13G/A | XENE / Xenon Pharmaceuticals Inc. | 2,800,000 | 4,985,000 | ||||
| 2022-02-11 | 13G/A | MRTX / Mirati Therapeutics, Inc. | 4,535,000 | 5,075,000 | ||||
| 2021-11-24 | 13D/A | XLRN / Acceleron Pharma Inc | 4,476,100 | 0 | ||||
| 2021-10-05 | 13D | XLRN / Acceleron Pharma Inc | 4,476,100 | |||||
| 2021-08-30 | 13D/A | AADI / Aadi Bioscience, Inc. | 4,500,000 | 2,211,752 | ||||
| 2021-06-04 | 13D | AADI / Aadi Bioscience, Inc. | 4,500,000 | |||||
| 2021-02-12 | 13G/A | MRNS / Marinus Pharmaceuticals, Inc. | 10,405,250 | 3,232,142 | ||||
| 2021-02-12 | 13G/A | KPTI / Karyopharm Therapeutics Inc. | 5,900,000 | 0 | ||||
| 2021-02-12 | 13G/A | XENE / Xenon Pharmaceuticals Inc. | 2,400,000 | 2,800,000 | ||||
| 2021-02-12 | 13G/A | CUE / Cue Biopharma, Inc. | 1,870,000 | 452,500 | ||||
| 2021-02-12 | 13G/A | ATNX / Athenex Inc | 5,261,437 | 372,500 | ||||
| 2021-02-12 | 13G/A | ALIM / Alimera Sciences, Inc. | 415,999 | 0 | ||||
| 2021-02-12 | 13G | PMVP / PMV Pharmaceuticals, Inc. | 2,350,267 | |||||
| 2021-02-12 | 13G | TRIL / Tidal Trust II - Defiance Trillion Dollar Club Index ETF | 5,800,000 | |||||
| 2021-02-12 | 13G | / Therapeutics Acquisition Corp. Class A | 1,000,000 | |||||
| 2021-02-12 | 13G | UTHR / United Therapeutics Corporation | 2,850,000 | |||||
| 2021-02-12 | 13G | KURA / Kura Oncology, Inc. | 4,000,000 | |||||
| 2021-02-12 | 13G | AVDL / Avadel Pharmaceuticals plc | 4,365,000 | |||||
| 2021-02-12 | 13G | ARNA / Arena Pharmaceuticals Inc | 4,190,000 | |||||
| 2021-02-12 | 13G | RLMD / Relmada Therapeutics, Inc. | 1,525,000 | |||||
| 2021-02-12 | 13G | MDGL / Madrigal Pharmaceuticals, Inc. | 1,225,000 | |||||
| 2021-02-12 | 13G | ISEE / IVERIC bio Inc | 7,250,000 | |||||
| 2021-02-12 | 13G | MRSN / Mersana Therapeutics, Inc. | 6,800,000 | |||||
| 2021-02-12 | 13G | GNCA / Genocea Biosciences Inc | 33,613,444 | |||||
| 2021-02-12 | 13G/A | IOVA / Iovance Biotherapeutics, Inc. | 8,826,039 | 7,500,000 | ||||
| 2021-02-12 | 13G/A | FENC / Fennec Pharmaceuticals Inc. | 1,105,999 | 1,670,000 | ||||
| 2021-02-12 | 13G/A | US2103731061 / Constellation Pharmaceuticals Inc | 3,650,000 | 2,950,000 | ||||
| 2021-02-12 | 13G/A | MRTX / Mirati Therapeutics, Inc. | 3,913,435 | 4,535,000 | ||||
| 2021-02-12 | 13G/A | ADVM / Adverum Biotechnologies, Inc. | 5,250,000 | 8,000,000 | ||||
| 2020-10-23 | 13D/A | IM3 / Immunomedics Inc | 21,000,000 | 0 | ||||
| 2020-09-01 | 13G | CBAY / CymaBay Therapeutics, Inc. | 5,500,000 | 10,300,000 | ||||
| 2020-02-24 | 13G/A | IOVA / Iovance Biotherapeutics, Inc. | 9,565,000 | 8,826,039 | ||||
| 2020-02-14 | 13G | CBAY / CymaBay Therapeutics, Inc. | 5,500,000 | |||||
| 2020-02-14 | 13G | KPTI / Karyopharm Therapeutics Inc. | 5,900,000 | |||||
| 2020-02-14 | 13G/A | IL0011177958 / Intec Pharma Ltd | 2,500,000 | 0 | ||||
| 2020-02-14 | 13G | CUE / Cue Biopharma, Inc. | 1,870,000 | |||||
| 2020-02-14 | 13G/A | TGTX / TG Therapeutics, Inc. | 4,750,000 | 1,000,000 | ||||
| 2020-02-14 | 13G | MRNS / Marinus Pharmaceuticals, Inc. | 10,405,250 | |||||
| 2020-02-14 | 13G/A | BDSI / Biodelivery Sciences International | 8,614,588 | 3,000,000 | ||||
| 2020-02-14 | 13G | ADVM / Adverum Biotechnologies, Inc. | 5,250,000 | |||||
| 2020-02-14 | 13G | US2103731061 / Constellation Pharmaceuticals Inc | 3,650,000 | |||||
| 2020-02-14 | 13G/A | FOLD / Amicus Therapeutics, Inc. | 10,125,000 | 11,200,000 | ||||
| 2020-02-14 | 13G/A | MRTX / Mirati Therapeutics, Inc. | 3,813,235 | 3,913,435 | ||||
| 2020-02-14 | 13G/A | TLGT / Teligent Inc | 5,300,000 | 0 | ||||
| 2020-02-14 | 13G/A | ALIM / Alimera Sciences, Inc. | 6,240,000 | 415,999 | ||||
| 2020-02-14 | 13G/A | IOVA / Iovance Biotherapeutics, Inc. | 11,000,000 | 9,565,000 | ||||
| 2020-02-14 | 13G | ATNX / Athenex Inc | 5,261,437 | |||||
| 2019-07-25 | 13G/A | MRTX / Mirati Therapeutics, Inc. | 4,798,101 | 3,813,235 | ||||
| 2019-07-01 | 13D/A | / Immunomedics, Inc. | 17,714,461 | 21,000,000 | ||||
| 2019-02-14 | 13G/A | ALIM / Alimera Sciences, Inc. | 6,241,581 | 6,240,000 | ||||
| 2019-02-14 | 13G/A | FENC / Fennec Pharmaceuticals Inc. | 1,105,999 | 1,105,999 | ||||
| 2019-02-14 | 13G/A | IOVA / Iovance Biotherapeutics, Inc. | 5,253,450 | 11,000,000 | ||||
| 2019-02-14 | 13G | XENE / Xenon Pharmaceuticals Inc. | 2,400,000 | |||||
| 2019-02-14 | 13G/A | TLGT / Teligent Inc | 5,049,431 | 5,300,000 | ||||
| 2019-02-14 | 13G | BDSI / Biodelivery Sciences International | 8,614,588 | |||||
| 2019-02-14 | 13G/A | MRTX / Mirati Therapeutics, Inc. | 3,748,101 | 4,798,101 | ||||
| 2019-02-14 | 13G | TGTX / TG Therapeutics, Inc. | 4,750,000 | |||||
| 2019-02-14 | 13G/A | FOLD / Amicus Therapeutics, Inc. | 8,763,122 | 10,125,000 | ||||
| 2019-02-14 | 13G/A | IL0011177958 / Intec Pharma Ltd | 2,195,705 | 2,500,000 | ||||
| 2018-06-19 | 13D/A | / Immunomedics, Inc. | 17,514,461 | 17,714,461 | ||||
| 2018-06-15 | 13D/A | / Immunomedics, Inc. | 16,939,461 | 17,514,461 | ||||
| 2018-02-12 | 13G | FOLD / Amicus Therapeutics, Inc. | 8,763,122 | |||||
| 2018-02-12 | 13G | IL0011177958 / Intec Pharma Ltd | 2,195,705 | |||||
| 2018-02-12 | 13G | FENC / Fennec Pharmaceuticals Inc. | 1,105,999 | |||||
| 2018-02-12 | 13G/A | ALIM / Alimera Sciences, Inc. | 4,520,643 | 6,241,581 | ||||
| 2018-02-12 | 13G/A | OTLK / Outlook Therapeutics, Inc. | 1,301,425 | 1,922,888 | ||||
| 2018-02-12 | 13G/A | IOVA / Iovance Biotherapeutics, Inc. | 3,187,607 | 5,253,450 | ||||
| 2018-02-12 | 13G | VIVE / Viveve Medical, Inc. | 1,033,276 | |||||
| 2018-02-12 | 13G | ASMB / Assembly Biosciences, Inc. | 1,068,534 | |||||
| 2018-02-12 | 13G | TLGT / Teligent Inc | 5,049,431 | |||||
| 2018-02-12 | 13G | CBIO / Crescent Biopharma, Inc. | 400,000 | |||||
| 2017-11-15 | 13D/A | / Immunomedics, Inc. | 10,488,076 | 16,939,461 | ||||
| 2017-10-03 | 13G/A | MRTX / Mirati Therapeutics, Inc. | 1,545,701 | 3,748,101 | ||||
| 2017-05-09 | 13D/A | / Immunomedics, Inc. | 10,488,076 | 10,488,076 | ||||
| 2017-03-17 | 13D/A | / Immunomedics, Inc. | 10,488,076 | 10,488,076 | ||||
| 2017-02-15 | 13D/A | / Immunomedics, Inc. | 9,564,140 | 10,488,076 | ||||
| 2017-02-09 | 13G/A | IOVA / Iovance Biotherapeutics, Inc. | 3,187,607 | 4,520,643 | ||||
| 2017-02-09 | 13G/A | ALIM / Alimera Sciences, Inc. | 4,034,488 | 4,520,643 | ||||
| 2017-02-09 | 13G | AGEN / Agenus Inc. | 4,750,430 | |||||
| 2017-02-09 | 13G/A | MRTX / Mirati Therapeutics, Inc. | 1,295,555 | 1,545,701 | ||||
| 2017-02-09 | 13G/A | IOVA / Iovance Biotherapeutics, Inc. | 3,187,607 | 4,520,643 | ||||
| 2017-02-09 | 13G | ALIM / Alimera Sciences, Inc. | 4,034,488 | |||||
| 2017-02-09 | 13G | OTLK / Outlook Therapeutics, Inc. | 1,301,425 | |||||
| 2016-11-16 | 13D | / Immunomedics, Inc. | 9,564,140 | |||||
| 2016-02-12 | 13G | IOVA / Iovance Biotherapeutics, Inc. | 3,187,607 | |||||
| 2016-02-12 | 13G | MRTX / Mirati Therapeutics, Inc. | 1,295,555 | |||||
| 2016-02-12 | 13G | PTX / Pernix Therapeutics Holdings, Inc. | 5,144,916 |
